clinical trial · NCT06613360
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
SLESLE (Systemic Lupus)CLN-978
brief summary
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
started
Jan 21, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2027
last updated
Mar 19, 2026
official title
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol